Abstract
SARS-CoV-2 virus, the etiologic agent of COVID-19 triggers a severe acute respiratory disease that leads to death in approximately 2% of the cases. In such a fragile scenario that involves the need to invest in vaccine strategies, it is necessary to prioritize versatile and safe vaccine strategies. Several studies have demonstrated the great potential of immunizations based on strategies …